Phase 2 randomized open-label study of momelotinib in anemia due to low-risk myelodysplastic syndrome

Phase 2, randomised, open-label trial of mivavotinib in myelodysplastic syndrome (MDS) (2 arms), sponsored by GSK. Primary endpoints: Percentage of participants with rolling 12 weeks of red blood cell transfusion independence by the end of Week 24, Selected safety endpoints and 1 more. Planned start Aug 2025; status: authorised.